Antiparasitic Chemotherapy and Mechanisms
Antiparasitic chemotherapy is the study of drugs used to kill or disable parasites of humans and animals, and of the molecular mechanisms by which those drugs act and through which parasites become resistant. Because parasites are eukaryotes (protozoa, helminths) or arthropods whose biochemistry overlaps with that of the host, the central problem of the field is achieving selective toxicity: harming the parasite far more than the host.
Definition
Antiparasitic chemotherapy is the use of chemical agents to treat or prevent infections caused by parasites, together with the pharmacological study of how those agents reach, recognise, and disrupt parasite-specific molecular targets while sparing the host.
Scope
This area orients the reader to the major drug classes used against protozoa, helminths, and ectoparasites; the cellular and biochemical targets they exploit; the principle of selective toxicity that distinguishes useful drugs from poisons; and the emergence and spread of drug resistance. It is an educational reference framework, not a prescribing or treatment guide.
Sub-topics
Core questions
- What parasite-specific targets can a drug exploit to achieve selective toxicity?
- How do the major classes of antiprotozoal and anthelmintic agents differ in mechanism?
- Why and how do parasites develop resistance, and how does resistance spread?
- What pharmacokinetic and host factors determine whether a drug reaches its parasite target?
Key concepts
- Selective toxicity
- Parasite-specific molecular targets
- Drug classes (antiprotozoal, anthelmintic, antimalarial, ectoparasiticide)
- Mechanism of action
- Drug resistance and its spread
- Pharmacokinetics in the host-parasite system
Mechanisms
Antiparasitic drugs work by binding molecular targets that are essential to the parasite and either absent, structurally divergent, or differently regulated in the host. Targets include parasite-specific enzymes and metabolic pathways, ion channels and neurotransmitter receptors of helminths, the malaria parasite's haem-detoxification machinery, and microtubules whose drug binding differs between parasite and host. Selective toxicity arises from these molecular differences and from differential drug uptake or accumulation. Resistance develops when target mutation, increased drug efflux, altered metabolism, or bypass of the affected pathway reduces drug effect, and it spreads under the selective pressure of drug exposure.
Clinical relevance
The drugs covered here underpin the control of malaria, the neglected tropical diseases, soil-transmitted helminthiases, and many veterinary infections, so understanding their mechanisms is central to appraising treatment evidence and resistance surveillance. This entry describes how antiparasitic agents act in general terms; it is not a basis for diagnosis, drug selection, or dosing in any individual.
Epidemiology
Parasitic diseases targeted by these agents impose a large global burden concentrated in low- and middle-income settings: malaria, leishmaniasis, African and American trypanosomiasis, schistosomiasis, and the soil-transmitted helminthiases are all addressed largely through chemotherapy and mass drug administration. Resistance to antimalarials and to anthelmintics is a recurring threat to these control efforts.
History
Antiparasitic chemotherapy is one of the oldest branches of pharmacology, with quinine from cinchona bark used against malaria for centuries. The twentieth century brought systematic drug discovery: synthetic antimalarials such as chloroquine, the avermectins and benzimidazoles for helminths, and the rediscovery of artemisinin from traditional Chinese medicine. Nobel Prizes recognising artemisinin and the avermectins underscored the field's continuing impact on global health.
Debates
- How should antiparasitic drugs be deployed to slow resistance?
- Strategies such as combination therapy, rotation, and restraint in mass drug administration are debated as ways to preserve drug efficacy, because heavy selective pressure repeatedly erodes the usefulness of antimalarials and anthelmintics.
Key figures
- Tu Youyou
- Satoshi Omura
- William C. Campbell
- Nicholas J. White
Related topics
Seminal works
- geary-2010
- white-2014
- goodman-gilman-2018
Frequently asked questions
- What makes designing antiparasitic drugs harder than antibacterials?
- Many parasites are eukaryotes whose cell biology resembles the human host's, so there are fewer parasite-unique targets to exploit, making selective toxicity more difficult to achieve.
- What is selective toxicity?
- It is the principle that a useful antiparasitic drug must damage the parasite far more than it damages the host, which depends on molecular differences between parasite and host targets or on differences in how the drug is taken up and accumulated.